– Conf Call
Inventiva And Hepalys Pharma, Inc. Announce Exclusive Licensing Agreement To Develop And Commercialize Lanifibranor In Japan And South Korea
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment,